Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Iclusig Tab 45Mg 30 By Ariad Pharma(Ponatinib Hydrochloride)

76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comINCYTE PHARMAInnocoll Biotherapeutics

Rx Item-Iclusig Tab 45Mg 30 By Ariad Pharma(Ponatinib Hydrochloride)

$0.00

item No.:RX76189-0534-30 NDC No.76189053430 UPC No.:376189534309 Iclusig tab 30 by ARIAD PHARMA(Ponatinib hydrochloride) NDC No. 76189-0534-30 76189053430 UPC/GTIN No. 3-76189-53430-9 376189-534309 376189534309 MPN 76189-534 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX item. Rx Item No. Rx76189-0534-30 Item Detai

Have a question?

  Out of stock, please email us with the item number or product link at [email protected] for the quantity available, current pricing and eligibility to purchase.

ICLUSIG- ponatinib hydrochloride tablet, film coated ARIAD Pharmaceuticals, Inc. WARNING: ARTERIAL OCCLUSION, VENOUS THROMBOEMBOLISM, HEART FAILURE, and HEPATOTOXICITY Arterial Occlusion: ​ Arterial occlusions have occurred in at least 35% of Iclusig-treated patients. Some patients experienced more than 1 type of event. Events observed included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of arterial occlusion. Interrupt or stop Iclusig immediately for arterial occlusion. A benefit-risk consideration should guide a decision to restart Iclusig therapy (5.1). Venous Thromboembolism Venous occlusive events have occurred in 6% of Iclusig-treated patients. Monitor for evidence of venous thromboembolism. Consider dose modification or discontinuation of Iclusig in patients who develop serious venous thromboembolism (5.2). Heart Failure: Heart failure, including fatalities, occurred in 9% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure (5.3). Hepatotoxicity: Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected (2.3, 5.4). 1 INDICATIONS AND USAGE ​ Iclusig (ponatinib) is a kinase inhibitor indicated for the: ​ Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated. ​ Treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ​ Limitations of use: ​ Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML [see Warnings and Precautions (5.7)]. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage The optimal dose of Iclusig has not been identified. In clinical trials, the starting dose of Iclusig was 45 mg administered orally once daily. However, in the phase 2 trial, 68% of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy. Start dosing with 45 mg once daily. Consider reducing the dose of Iclusig for patients with chronic phase (CP) CML and accelerated phase (AP) CML who have achieved a major cytogenetic response. Consider discontinuing Iclusig if response has not occurred by 3 months (90 days). Iclusig may be taken with or without food. Tablets should be swallowed whole. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR-ABL when compared to controls.

76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)
RX ITEM-Iclusig Tab 45Mg 30 By Ariad Pha
76189-0534-30 76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)

76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG 45MG TAB
76189-0534-30 76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)

76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG 45MG TAB
76189-0534-30 76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)

Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG TAB
Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)

76189-0534-30  76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG 45MG TAB
76189-0534-30 76189053430 Iclusig tab 45mg 30 by ARIAD PHARMA(Ponatinib hydrochloride)

Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG TAB
Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)

Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG TAB
Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)

Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG TAB
Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)

Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)
ICLUSIG TAB
Iclusig tab by ARIAD PHARMA(Ponatinib hydrochloride)

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

INCYTE PHARMA
INCYTE PHARMA
INCYTE PHARMA

Innocoll Biotherapeutics
Innocoll Biotherapeutics
Innocoll Biotherapeutics